Novo Nordisk's latest trial results for its next-generation obesity drug CagriSema disappointed investors by failing to show ...

Novo Nordisk has defended disappointing trial results for its much-hyped next generation obesity drug candidate CagriSema, insisting it will be an “important” weight loss treatment.

As Novo Nordisk A/S shares head for their worst month in more than two decades, the days when the Danish drugmaker was valued ...

Novo Nordisk has experienced a 50% drop due to potential tariffs and recent clinical trial results. Read why I rate NVO stock a strong buy right now.

With promising new obesity treatments in the pipeline, 24/7 Wall St. projects huge upside for Novo Nordisk stock through 2030 ...

Novo Nordisk’s stocks experienced the sharpest monthly decline since July 2002 due to growing competition and several ...

Novo Nordisk's hopes of heralding a new era of obesity treatment with its CagriSema drug have been called into question after a series of trial results sent shares falling. Headline results from a ...